RecruitingNCT03877796

Clinical Pre-screening Protocol for Ovarian Cancer

Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer

Sponsor

Allarity Therapeutics

Enrollment

60 participants

Start Date

Apr 11, 2019

Study Type

OBSERVATIONAL

Conditions

Ovarian Cancer

Summary

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a pre-screening study for women with ovarian cancer that has stopped responding to standard platinum-based chemotherapy. The goal is to test tumor tissue to determine which women might be eligible for specific targeted treatments or other clinical trials, helping match patients to the most appropriate next therapy. **You may be eligible if...** - You have ovarian cancer confirmed by biopsy (epithelial type) - Your cancer is no longer responding to platinum chemotherapy — progressed within 6 months of your last platinum treatment, or you are ineligible for platinum - You have received no more than one prior treatment after your cancer became platinum-resistant - Tumor tissue samples (FFPE blocks) are available for testing **You may NOT be eligible if...** - Your cancer progressed while you were still actively receiving platinum chemotherapy - You have another active cancer, with certain exceptions for cured early-stage cancers Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.